A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
PHASE1
The primary objective of the study is to evaluate the pharmacokinetic (PK) ...
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
EARLY_PHASE1
The purpose of this study is to assess the safety and feasibility of admini...
Status
Active Not Recruiting
Location
West Virginia University Rockefeller Neuroscience Institute
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
PHASE2
The primary objective of the study is to assess the safety impact of contin...